- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Daratumumab – November 2017
Daratumumab : Solution concentrate for I.V infusion 100 mg in 5 mL, Solution concentrate for I.V infusion 400 mg in 20 mL; Darzalex®
Last updated
16 March 2018